129th MAINE LEGISLATURE
		LD 793		LR 1130(02)
	An Act To Improve Accountability of Opioid Manufacturers
	Fiscal Note for Bill as Amended by Committee Amendment " "
	Committee: Judiciary
	Fiscal Note Required: Yes
Fiscal Note
Current biennium revenue increase - Other Special Revenue Funds
			FY 2019-20	FY 2020-21	Projections  FY 2021-22	Projections  FY 2022-23
Appropriations/Allocations
	Other Special Revenue Funds		$53,500	$53,500	$53,500	$3,500
Fiscal Detail and Notes
	This bill includes Other Special Revenue Funds allocations of $53,000 in fiscal year 2019-20 and $53,000 in fiscal year 2020-21 to the Licensing and Enforcement program within the Department of Professional and Financial Regulation for the contracting and general operating costs associated with the development of the registration fee review report, determination and report of exempted medications, rulemaking and additional board meetings.
	This bill raises the annual license fee for a manufacturer of opiod medication to $55,000 and establishes an annual registration fee of $250,000 for a manufacturer of an opioid product that sells, delivers or distributes an opioid medication in the State and requires that the revenue from these fees, excluding $325 per license that may be retained by the Department of Professional and Financial Regulation, be credited to the Opiod Use Disorder Prevention and Treatment Fund.  The estimated revenue to be received from the license and registration fees can not be estimated at this time.
	The bill also includes Other Special Revenue Funds allocations to the Department of Health and Human Services of $500 beginning in fiscal year 2019-20 for the base allocation for the Opioid Use Disorder Prevention and Treatment Fund.